Abstract: Methods and assays for monitoring the cardiac health of a subject are provided. The method involves the detection of a urotensin surrogate in a sample leading to a more accurate and reliable diagnosis of early or late stages of decompensated heart failure, heart failure, risk of a heart failur in a subject than the measurement of the cyclic peptide of urotensin alone.

Abstract: A device for remote management of patients suffering or likely to suffer from heart failure that can measure the amplitude and frequency changes of one or more biomarkers. The device aids in predicting the need for medical intervention in such patients. The device may further aid in monitoring the efficacy and safety of treatment in such patients.

Abstract: An assay device includes a first reagent including a magnetic particle and a second reagent including detectable component. The first and second reagent can each independently bind to an analyte in a sample. A time-varying magnetic field can be used to distinguish detectable components that are associated with analyte from detectable components not associated with analyte.

Abstract: A method of determining the presence or amount of analyte in a fluid sample, which comprises: contacting a fluid sample with a binding reagent that comprises a plurality of cleavable species and wherein said species, when cleaved, are detectable using electrochemical means; separating any binding reagent-analyte complex that forms from the unbound binding reagent; cleaving the cleavable species from the immobilized binding reagent-analyte complex; and detecting the cleaved species using electrochemical means.

Abstract: Medical and environmental diagnostic devices are described and claimed. Preferred embodiments feature cup (1) within cup configurations wherein one cup is dedicated, for the most part, to sample collection and another cup (2) is dedicated, for the most part, to assay performance. Communication between the cups is afforded by what is believed to be a unique valve assembly (3) and lid (7) tandem.

Abstract: A purified peptide mimotope which is capable of binding specifically to an antibody specific to estradiol. Also disclosed is an immunoassay test device for the detection in a sample of estradiol, the immunoassay test device comprising a peptide mimotope of estradiol, and an antibody capable of binding specifically to the peptide mimotope to generate a detectable signal.

Abstract: A device for the collection of oral fluid from a subject's oral cavity may include a sample-collecting mouthpiece and a one-way valve. The mouthpiece may include a collecting chamber, introducible into the oral cavity of the subject for collecting oral fluid, and a resiliently deformable wall section defining at least part of the collecting chamber such that compression of the resiliently deformable wall forcibly expels a collected fluid from the collecting chamber via a collecting chamber outlet. The one-way valve may be in fluid communication with the collecting chamber outlet and may allow fluid to be displaced from the device following compression of the resiliently deformable wall but prevents ambient air flowing back through the valve into the device.

Abstract: An analysis device is provided for analysing a substance sample. The device comprises a plurality of sample activatable battery cells connected in series.

Abstract: Rapid lateral flow immunoassays have an extensive history of use in both the clinical and home settings. These devices are used to test for a variety of analytes, such as drugs of abuse, hormones, proteins, urine or plasma components and the like. The present invention provides an improved procedural control that indicates to the test user that at least a portion of the applied sample has passed through the test result zone of the test strip, and optionally that the test is complete and the test results may be read.

Abstract: Novel methods and devices comprising magnetic particles for detecting or monitoring the coagulation state of a sample are provided.

Abstract: The present invention is directed to devices and methods for collecting liquid samples and of testing the sample for the presence of an analyte of interest and/or a physical property. In one embodiment the device is a urine cup having an interior for containing a liquid sample, a lid, and a chamber for holding liquid. The device contains a test component for determining the presence of an analyte in the liquid sample and/or a physical property. A tube is immersed in liquid sample when the device is filled with liquid sample to be tested. When the lid is applied to the device (e.g., by screwing or snapping on), liquid sample is forced through the tube and into the chamber holding the test component.

Abstract: A method of patterning a bibulous substrate is disclosed. The method comprises contacting the bibulous substrate with a first surface being coated by a barrier compound, using a second surface having a predetermined pattern engraved thereon, and applying heat and pressure onto the first surface such as to pattern the bibulous substrate in a predetermined pattern.

Abstract: A device for determining an assay result may include a test strip, a light source system, a light detection system, and a processor.

Abstract: There is disclosed a lateral flow assay device and method of producing the same. The device, which is for identifying carbohydrate antigens in a biological sample comprises a substrate having, a) a sample receiving zone, b) an extraction zone for receiving the sample from said sample receiving zone and which extraction zone comprises immobilised or otherwise absorbed therein at least one or more reactants and reagents which when combined react to form an extraction reagent for a desired antigen in said sample, said sample to be added to said sample receiving zone optionally comprising the remaining reactant required to form said extraction reagent if not present in said extraction zone, c) optionally a neutralising agent capable of bringing the pH of the resulting sample to within the operational pH range of the assay and, d) a detection zone for a labelled specific binding or capture reagent for said antigen to be detected.

Abstract: A method and test device for differentiating between states of an analyte that can exist in different forms, such as follicle stimulating hormone (FSH). The method or test device uses a pair of specific binding agents, especially monoclonal antibodies, in two assays for the same analyte. The assays, applied to contemporaneous samples, differ from one another in format, one being a two step assay and the other being one step. A novel pair of anti-FSH monoclonal antibodies that can be used together in two such assays to differentiate pre-menopausal and post-menopausal FSH samples is disclosed.

Abstract: An analytical test device incorporating a dry porous carrier to which a liquid sample, eg. urine, suspected of containing an analyte such as HCG or LH can be applied indirectly, the device also incorporating a labelled specific binding reagent which is freely mobile in the porous carrier when in the moist state, and an unlabelled specific binding reagent which is permanently immobilised in a detection zone on the carrier material, the labelled and unlabelled specific binding reagents being capable of participating in either a sandwich reaction or a competition reaction in the presence of the analyte, in which prior to the application to the device of a liquid sample suspected of containing the analyte, the labelled specific binding reagent is retained in the dry state in a macroporous body, eg.